ArticleBMC medicine2025
Pathology-interpretable radiomic model for predicting clinical outcome in patients with osteosarcoma: a retrospective, multicenter study.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Understanding and Overcoming Osteosarcoma Heterogeneity.Biomolecules · 2026Review
- Preoperative differentiation of primary vs. metastatic lumbar spine tumors: development and external validation of a multiparametric MRI-based radiomics nomogram.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundOsteosarcoma is the most prevalent primary malignant bone tumor. Radiomic models show promise in globally evaluating the prognosis of osteosarcoma; however, they lack biological interpretability. We aimed to develop a radiomic model using MRI to predict disease-free survival (DFS) in osteosarcoma patients and provide the underlying pathobiology of the model.
methodsThis retrospective study included 270 patients (training set, n = 166; external test set 1, n = 56; external test set 2, n = 48) with surgically treated and histology-proven osteosarcoma from 14 tertiary centers. A total of 1130 radiomic features were extracted from baseline MRI data. After dimensionality reduction, the radiomic model was developed on the training set and tested on the external test sets. The radiomics interpretability study used the hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stained whole slide images (WSIs) of patients from the testing sets. Ten types of nuclear morphological features were extracted from each nucleus in H&E WSIs and aggregated into 150 patient-level features. Furthermore, five immune- and hypoxia-related IHC biomarkers, including CD3, CD8, CD68, FOXP3, and CAIX, were quantified from IHC WSIs. The correlation between the radiomic features and histopathologic markers was assessed using Spearman or Pearson correlation analysis, with multiple hypothesis testing controlled by the false discovery rate.
resultsThe radiomic model comprising 12 features yielded a time-dependent AUC of 0.916 (95% CI: 0.893-0.939), 0.802 (95% CI: 0.763-0.840), and 0.895 (95% CI: 0.869-0.920) in the training set, external test set 1, and external test set 2, respectively. Notably, nine out of 12 radiomic features exhibited significant correlations with 17 cellular features, resulting in 32 pairs. Specifically, there were four (12.5%) pairs with absolute coefficient r (|r|) between 0.3 and 0.4, 22 (68.8%) pairs between 0.4 and 0.5, and six (18.8%) pairs exceeding 0.5. Four radiomic features were correlated with CD3 (r = 0.50-0.75), two features with CD8 (r = 0.46 and 0.60), and three features with CD8/FOXP3 (r = 0.69-0.81).
conclusionsThe MRI-based radiomic model shows potential in predicting DFS in osteosarcoma patients. Most radiomic features show only moderate associations with H&E-derived nuclear morphological features; they exhibit higher correlations with immune-related biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.